-
1
-
-
0035142923
-
Prognostic value of vascularity and vascular endothelial growth factor expression in non-small cell lung cancer
-
Baillie R, Carlile J, Pendleton N, Schor AM (2001) Prognostic value of vascularity and vascular endothelial growth factor expression in non-small cell lung cancer. J Clin Pathol 54: 116-120.
-
(2001)
J Clin Pathol
, vol.54
, pp. 116-120
-
-
Baillie, R.1
Carlile, J.2
Pendleton, N.3
Schor, A.M.4
-
2
-
-
47949099628
-
Modes of resistance to anti-angiogenic therapy
-
Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8: 592-603.
-
(2008)
Nat Rev Cancer
, vol.8
, pp. 592-603
-
-
Bergers, G.1
Hanahan, D.2
-
3
-
-
84860780755
-
A phase i study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
-
Boss DS, Glen H, Beijnen JH, Keesen M, Morrison R, Tait B, Copalu W, Mazur A, Wanders J, O'Brien JP, Schellens JH, Evans TR (2012) A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours. Br J Cancer 106: 1598-1604.
-
(2012)
Br J Cancer
, vol.106
, pp. 1598-1604
-
-
Boss, D.S.1
Glen, H.2
Beijnen, J.H.3
Keesen, M.4
Morrison, R.5
Tait, B.6
Copalu, W.7
Mazur, A.8
Wanders, J.9
O'Brien, J.P.10
Schellens, J.H.11
Evans, T.R.12
-
4
-
-
84883186017
-
-
Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0, DCTD, NCI, NIH, DHHS http://ctep.cancer.gov Accessed 2012
-
Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0, DCTD, NCI, NIH, DHHS http://ctep.cancer.gov (2006) http://ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ ctcaev3.pdf. Accessed (2012).
-
(2006)
-
-
-
5
-
-
0038363443
-
Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2
-
Cao R, Bråkenhielm E, Pawliuk R, Wariaro D, Post MJ, Wahlberg E, Leboulch P, Cao Y (2003) Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 9: 604-613.
-
(2003)
Nat Med
, vol.9
, pp. 604-613
-
-
Cao, R.1
Bråkenhielm, E.2
Pawliuk, R.3
Wariaro, D.4
Post, M.J.5
Wahlberg, E.6
Leboulch, P.7
Cao, Y.8
-
6
-
-
77950402591
-
Co-expression of PDGF-B and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small-cell lung cancer
-
Donnem T, Al-Saad S, Al-Shibli K, Busund LT, Bremnes RM (2010) Co-expression of PDGF-B and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small-cell lung cancer. Ann Oncol 21: 223-231.
-
(2010)
Ann Oncol
, vol.21
, pp. 223-231
-
-
Donnem, T.1
Al-Saad, S.2
Al-Shibli, K.3
Busund, L.T.4
Bremnes, R.M.5
-
7
-
-
58149190795
-
Pathways mediating resistance to vascular endothelial growth factor-targeted therapy
-
Ellis LM, Hicklin DJ (2008) Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res 14: 6371-6375.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 6371-6375
-
-
Ellis, L.M.1
Hicklin, D.J.2
-
8
-
-
4143136640
-
Vascular endothelial growth factor: Basic science and clinical progress
-
Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: 581-611.
-
(2004)
Endocr Rev
, vol.25
, pp. 581-611
-
-
Ferrara, N.1
-
9
-
-
73949092851
-
Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study
-
Goss GD, Arnold A, Shepherd FA, Dediu M, Ciuleanu TE, Fenton D, Zukin M, Walde D, Laberge F, Vincent MD, Ellis PM, Laurie SA, Ding K, Frymire E, Gauthier I, Leighl NB, Ho C, Noble J, Lee CW, Seymour L (2010) Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 28: 49-55.
-
(2010)
J Clin Oncol
, vol.28
, pp. 49-55
-
-
Goss, G.D.1
Arnold, A.2
Shepherd, F.A.3
Dediu, M.4
Ciuleanu, T.E.5
Fenton, D.6
Zukin, M.7
Walde, D.8
Laberge, F.9
Vincent, M.D.10
Ellis, P.M.11
Laurie, S.A.12
Ding, K.13
Frymire, E.14
Gauthier, I.15
Leighl, N.B.16
Ho, C.17
Noble, J.18
Lee, C.W.19
Seymour, L.20
more..
-
10
-
-
0036849944
-
The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of non-small cell lung cancer
-
Inoshima N, Nakanishi Y, Minami T, Izumi M, Takayama K, Yoshino I, Hara N (2002) The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of non-small cell lung cancer. Clin Cancer Res 8: 3480-3486.
-
(2002)
Clin Cancer Res
, vol.8
, pp. 3480-3486
-
-
Inoshima, N.1
Nakanishi, Y.2
Minami, T.3
Izumi, M.4
Takayama, K.5
Yoshino, I.6
Hara, N.7
-
11
-
-
79952232216
-
Global cancer statistics
-
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
-
(2011)
CA Cancer J Clin
, vol.61
, pp. 69-90
-
-
Jemal, A.1
Bray, F.2
Center, M.M.3
Ferlay, J.4
Ward, E.5
Forman, D.6
-
12
-
-
32644455074
-
A phase i study of carboplatin
-
Kimura K, Kato T, Takamizawa H, Tari K, Suzuoki Y, Sekiba K, Fukuoka L, Akimoto M, Abe O, Santo M, Niitani H, Furuse K, Ohta K, Kimura I, Konno K, Honma T, Tominaga K, Niijima T, Inagaki J (1988) A phase I study of carboplatin. Oncologia 21: 88-94.
-
(1988)
Oncologia
, vol.21
, pp. 88-94
-
-
Kimura, K.1
Kato, T.2
Takamizawa, H.3
Tari, K.4
Suzuoki, Y.5
Sekiba, K.6
Fukuoka, L.7
Akimoto, M.8
Abe, O.9
Santo, M.10
Niitani, H.11
Furuse, K.12
Ohta, K.13
Kimura, I.14
Konno, K.15
Honma, T.16
Tominaga, K.17
Niijima, T.18
Inagaki, J.19
-
13
-
-
84856462493
-
Adding to the mix: Fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer
-
Kono SA, Heasley LE, Doebele RC, Camidge DR (2012) Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in non-small cell lung cancer. Curr Cancer Drug Targets 12: 107-123.
-
(2012)
Curr Cancer Drug Targets
, vol.12
, pp. 107-123
-
-
Kono, S.A.1
Heasley, L.E.2
Doebele, R.C.3
Camidge, D.R.4
-
14
-
-
37349105704
-
E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition
-
Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, Uenaka T, Asada M (2008a) E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer 122: 664-671.
-
(2008)
Int J Cancer
, vol.122
, pp. 664-671
-
-
Matsui, J.1
Yamamoto, Y.2
Funahashi, Y.3
Tsuruoka, A.4
Watanabe, T.5
Wakabayashi, T.6
Uenaka, T.7
Asada, M.8
-
15
-
-
53049085556
-
Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumour MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase
-
Matsui J, Funahashi Y, Uenaka T, Watanabe T, Tsuruoka A, Asada M (2008b) Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumour MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 14: 5459-5465.
-
(2008)
Clin Cancer Res
, vol.14
, pp. 5459-5465
-
-
Matsui, J.1
Funahashi, Y.2
Uenaka, T.3
Watanabe, T.4
Tsuruoka, A.5
Asada, M.6
-
16
-
-
44249086425
-
Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship
-
Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83: 584-594.
-
(2008)
Mayo Clin Proc
, vol.83
, pp. 584-594
-
-
Molina, J.R.1
Yang, P.2
Cassivi, S.D.3
Schild, S.E.4
Adjei, A.A.5
-
17
-
-
3042855669
-
Expression of vascular endothelial growth factor-A and vascular endothelial growth factor-C as prognostic factors for nonsmall cell lung cancer
-
Nakashima T, Huang CL, Liu D, Kameyama K, Masuya D, Ueno M, Haba R, Yokomise H (2004) Expression of vascular endothelial growth factor-A and vascular endothelial growth factor-C as prognostic factors for nonsmall cell lung cancer. Med Sci Monit 10: BR157-BR165.
-
(2004)
Med Sci Monit
, vol.10
-
-
Nakashima, T.1
Huang, C.L.2
Liu, D.3
Kameyama, K.4
Masuya, D.5
Ueno, M.6
Haba, R.7
Yokomise, H.8
-
18
-
-
70449095638
-
Phase i dose-escalation study of E7080, a multikinase inhibitor, in patients with advanced solid tumors [abstract]
-
abstract 14583
-
Nemunaitis JJ, Senzer NN, Kurzrock R, Ng CS, Das A, Atienza RS, Zang EA, Jansen M, Ashworth S, Hong DS (2008) Phase I dose-escalation study of E7080, a multikinase inhibitor, in patients with advanced solid tumors [abstract]. J Clin Oncol 26 (Suppl 634s): abstract 14583.
-
(2008)
J Clin Oncol
, vol.26
, Issue.SUPPL. 634
-
-
Nemunaitis, J.J.1
Senzer, N.N.2
Kurzrock, R.3
Ng, C.S.4
Das, A.5
Atienza, R.S.6
Zang, E.A.7
Jansen, M.8
Ashworth, S.9
Hong, D.S.10
-
19
-
-
53749097825
-
Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials
-
NSCLC Meta-Analyses Collaborative Group
-
NSCLC Meta-Analyses Collaborative Group (2008) Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 26: 4617-4625.
-
(2008)
J Clin Oncol
, vol.26
, pp. 4617-4625
-
-
-
20
-
-
84860505684
-
Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer
-
JO19907 Study Group
-
Niho S, Kunitoh H, Nokihara H, Horai T, Ichinose Y, Hida T, Yamamoto N, Kawahara M, Shinkai T, Nakagawa K, Matsui K, Negoro S, Yokoyama A, Kudoh S, Kiura K, Mori K, Okamoto H, Sakai H, Takeda K, Yokota S, Saijo N, Fukuoka M. JO19907 Study Group (2012) Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer 76: 362-367.
-
(2012)
Lung Cancer
, vol.76
, pp. 362-367
-
-
Niho, S.1
Kunitoh, H.2
Nokihara, H.3
Horai, T.4
Ichinose, Y.5
Hida, T.6
Yamamoto, N.7
Kawahara, M.8
Shinkai, T.9
Nakagawa, K.10
Matsui, K.11
Negoro, S.12
Yokoyama, A.13
Kudoh, S.14
Kiura, K.15
Mori, K.16
Okamoto, H.17
Sakai, H.18
Takeda, K.19
Yokota, S.20
Saijo, N.21
Fukuoka, M.22
more..
-
21
-
-
34948905351
-
Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumour neovascularization and metastasis
-
Nissen LJ, Cao R, Hedlund EM, Wang Z, Zhao X, Wetterskog D, Funa K, Bråkenhielm E, Cao Y (2007) Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumour neovascularization and metastasis. J Clin Invest 117: 2766-2777.
-
(2007)
J Clin Invest
, vol.117
, pp. 2766-2777
-
-
Nissen, L.J.1
Cao, R.2
Hedlund, E.M.3
Wang, Z.4
Zhao, X.5
Wetterskog, D.6
Funa, K.7
Bråkenhielm, E.8
Cao, Y.9
-
22
-
-
33847276516
-
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan
-
Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y, Fukuoka M (2007) Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18: 317-323.
-
(2007)
Ann Oncol
, vol.18
, pp. 317-323
-
-
Ohe, Y.1
Ohashi, Y.2
Kubota, K.3
Tamura, T.4
Nakagawa, K.5
Negoro, S.6
Nishiwaki, Y.7
Saijo, N.8
Ariyoshi, Y.9
Fukuoka, M.10
-
23
-
-
33845490014
-
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
-
Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542-2550.
-
(2006)
N Engl J Med
, vol.355
, pp. 2542-2550
-
-
Sandler, A.1
Gray, R.2
Perry, M.C.3
Brahmer, J.4
Schiller, J.H.5
Dowlati, A.6
Lilenbaum, R.7
Johnson, D.H.8
-
24
-
-
77951639655
-
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer
-
Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, Abrão Miziara JE, Balint B, De Marinis F, Keller A, Arén O, Csollak M, Albert I, Barrios CH, Grossi F, Krzakowski M, Cupit L, Cihon F, Dimatteo S, Hanna N (2010) Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 28: 1835-1842.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1835-1842
-
-
Scagliotti, G.1
Novello, S.2
Von Pawel, J.3
Reck, M.4
Pereira, J.R.5
Thomas, M.6
Abrão Miziara, J.E.7
Balint, B.8
De Marinis, F.9
Keller, A.10
Arén, O.11
Csollak, M.12
Albert, I.13
Barrios, C.H.14
Grossi, F.15
Krzakowski, M.16
Cupit, L.17
Cihon, F.18
Dimatteo, S.19
Hanna, N.20
more..
-
25
-
-
84857407325
-
Fibroblast growth factor signaling in non-smallcell lung cancer
-
Semrad TJ, Mack PC (2012) Fibroblast growth factor signaling in non-smallcell lung cancer. Clin Lung Cancer 13: 90-95.
-
(2012)
Clin Lung Cancer
, vol.13
, pp. 90-95
-
-
Semrad, T.J.1
MacK, P.C.2
-
26
-
-
50349097617
-
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: Implications for antiangiogenic drugs as chemosensitizing agents
-
Shaked Y, Henke E, Roodhart JM, Mancuso P, Langenberg MH, Colleoni M, Daenen LG, Man S, Xu P, Emmenegger U, Tang T, Zhu Z, Witte L, Strieter RM, Bertolini F, Voest EE, Benezra R, Kerbel RS (2008) Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 14: 263-273.
-
(2008)
Cancer Cell
, vol.14
, pp. 263-273
-
-
Shaked, Y.1
Henke, E.2
Roodhart, J.M.3
Mancuso, P.4
Langenberg, M.H.5
Colleoni, M.6
Daenen, L.G.7
Man, S.8
Xu, P.9
Emmenegger, U.10
Tang, T.11
Zhu, Z.12
Witte, L.13
Strieter, R.M.14
Bertolini, F.15
Voest, E.E.16
Benezra, R.17
Kerbel, R.S.18
-
27
-
-
79960037492
-
Tyrosine kinase receptor Flt/VEGFR family: Its characterization related to angiogenesis and cancer
-
Shibuya M (2010) Tyrosine kinase receptor Flt/VEGFR family: its characterization related to angiogenesis and cancer. Genes Cancer 1: 1119-1123.
-
(2010)
Genes Cancer
, vol.1
, pp. 1119-1123
-
-
Shibuya, M.1
-
28
-
-
0029417264
-
Phase i study of paclitaxel by three-hour infusion: Hypotension just after infusion is one of the major dose-limiting toxicities
-
Tamura T, Sasaki Y, Nishiwaki Y, Saijo N (1995) Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities. Jpn J Cancer Res 86: 1203-1209.
-
(1995)
Jpn J Cancer Res
, vol.86
, pp. 1203-1209
-
-
Tamura, T.1
Sasaki, Y.2
Nishiwaki, Y.3
Saijo, N.4
-
29
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors
-
European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
Wanders, J.4
Kaplan, R.S.5
Rubinstein, L.6
Verweij, J.7
Van Glabbeke, M.8
Van Oosterom, A.T.9
Christian, M.C.10
Gwyther, S.G.11
-
30
-
-
75149170979
-
Fibroblast growth factor signalling: From development to cancer
-
Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10: 116-129.
-
(2010)
Nat Rev Cancer
, vol.10
, pp. 116-129
-
-
Turner, N.1
Grose, R.2
-
31
-
-
79954609271
-
Phase i dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors
-
Yamada K, Yamamoto N, Yamada Y, Nokihara H, Fujiwara Y, Hirata T, Koizumi F, Nishio K, Koyama N, Tamura T (2011) Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. Clin Cancer Res 17: 2528-2537.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 2528-2537
-
-
Yamada, K.1
Yamamoto, N.2
Yamada, Y.3
Nokihara, H.4
Fujiwara, Y.5
Hirata, T.6
Koizumi, F.7
Nishio, K.8
Koyama, N.9
Tamura, T.10
|